Apnées tardives du prématuré : facteurs de risque, traitement ambulatoire par citrate de caféine

Ducrocq, S.; Biran-Mucignat, V.; Boelle, P.; Lebas, François; Baudon, J; Gold, F.

doi:10.1016/j.arcped.2006.06.016

Cited by 6 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AOP disappears in most infants by 36 to 40 weeks postconceptional age. However, extremely premature infants (24–28 gestational weeks) are at risk for experiencing apnea beyond 38 to 40 weeks postconceptional age [29]. …”

Section: Consequences Of Aopmentioning

confidence: 99%

Apnea of prematurity: from cause to treatment

2011

View full text Add to dashboard Cite

Apnea of prematurity (AOP) is a common problem affecting premature infants, likely secondary to a “physiologic” immaturity of respiratory control that may be exacerbated by neonatal disease. These include altered ventilatory responses to hypoxia, hypercapnia, and altered sleep states, while the roles of gastroesophageal reflux and anemia remain controversial. Standard clinical management of the obstructive subtype of AOP includes prone positioning and continuous positive or nasal intermittent positive pressure ventilation to prevent pharyngeal collapse and alveolar atelectasis, while methylxanthine therapy is a mainstay of treatment of central apnea by stimulating the central nervous system and respiratory muscle function. Other therapies, including kangaroo care, red blood cell transfusions, and CO2 inhalation, require further study. The physiology and pathophysiology behind AOP are discussed, including the laryngeal chemoreflex and sensitivity to inhibitory neurotransmitters, as are the mechanisms by which different therapies may work and the potential long-term neurodevelopmental consequences of AOP and its treatment.

show abstract

Section: Consequences Of Aopmentioning

confidence: 99%

Apnea of prematurity: from cause to treatment

2011

View full text Add to dashboard Cite

show abstract

“…The apnea of premature infants is an interruption of breathing for >15 sec and is accompanied by hypoxia or bradycardia, which is a risk factor for the damage to a developing brain ( 1 , 2 ). Although the apnea usually resolves by the time the infant reaches 36-37 weeks of age ( 3 ), the incidence of the disease is higher in the neonates born at 30-31 weeks ( 4 ). Within clinical practice, apnea is classified into three types: Central, obstructive and mixed, and the mixed type accounts for 50% of apnea events ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

“…The management of the apnea of prematurity involves a combination of two major therapies, a pharmacological treatment and the supply of O 2 , which is necessary for normal body function ( 1 , 3 , 6 ). Although caffeine citrate and aminophylline have been the primary treatments of infant apnea within clinical practice ( 8 ), a comparison of the efficacy and safety of both drugs in the treatment of apnea still remains to be performed, particularly for those who underwent different strategies of O 2 supply.…”

Section: Introductionmentioning

confidence: 99%

Caffeine versus aminophylline in combination with oxygen therapy for apnea of prematurity: A retrospective cohort study

et al. 2020

View full text Add to dashboard Cite

The present study was conducted to investigate the clinical significance of caffeine and aminophylline in the treatment of premature infants with apnea under varying conditions of oxygen (O 2) delivery. The clinical data of 120 premature infants with apnea treated with oxygen therapy and either caffeine citrate (20 mg/kg/day; n=77) or aminophylline (10 mg/kg/day; n=43) were retrospectively examined. The therapeutic performance of the drugs after the completion of the treatment was evaluated primarily according to the risk of recurrent episodes of apnea, the changes in the duration and concentration of inhaled O 2 and the incidence of complications. In contrast to aminophylline, caffeine treatment significantly reduced the duration of O 2 inhalation and the inhaled O 2 concentration in the infants treated with mechanical ventilation or O 2 delivery devices (P<0.05). Treatment with caffeine also decreased the incidence of recurrent apnea events and complications in the investigated population (P<0.05 or P<0.01). Caffeine performs better than aminophylline in the treatment of premature infants with apnea under different conditions of O 2 delivery. The therapeutic performance of caffeine is achieved primarily via improving the efficacy of supplemental O 2 and reducing the incidence of complications.

show abstract